18F-FDG PET/CT优化新发转移性鼻咽癌M1分期分层
该单中心回顾性研究纳入185例2000–2022年新发转移性鼻咽癌患者,分析治疗前18F-FDG PET/CT所示转移负荷对AJCC第9版M1亚分期的验证价值,并探索基于PET的优化分类。结果显示单器官且≤4个病灶者总生存更优,>5个病灶与更差OS独立相关,优化分类的预后区分度优于AJCC第9版,但需外部验证。
要点
- 单器官且≤4个转移灶患者2年OS 60.4%、3年OS 46.2%,优于对照组的29.0%与19.6%。
- 转移灶>5个与更差OS独立相关(HR 1.81,95%CI 1.24-2.64,P=0.002)。
- 基于PET的优化分类预后区分度优于AJCC第9版(C-index 0.594 vs 0.562)。
核心结论
- 18F-FDG PET/CT通过量化转移负荷与分布,可能提升新发转移性鼻咽癌的M1分期预后准确性。
- 基于PET的优化分类较AJCC第9版显示出更好的预后区分度,但仅为初步证据,需外部验证。
研究设计与样本
- 单中心回顾性队列,纳入2000–2022年诊断的185例新发转移性鼻咽癌患者,均接受治疗前18F-FDG PET/CT。
- 采用递归分割分析(RPA)确定转移灶的预后截断值,比较AJCC第9版M1亚组与基于PET的重新定义分类的生存结局。
主要发现
- 单器官转移且≤4个病灶者2年OS为60.4% vs 29.0%,3年OS为46.2% vs 19.6%(P<0.001)。
- 转移负荷>5个病灶与更差OS独立相关(HR 1.81,95%CI 1.24-2.64,P=0.002)。
- 基于PET的优化分类C-index为0.594 vs AJCC第9版0.562,36个月AUC为0.649 vs 0.598。
- Rd-M1b组OS显著劣于Rd-M1a组(HR 2.02,95%CI 1.39-2.92,P=0.002)。
关键数值与推荐
- AJCC第9版M1a定义为≤3个转移灶,M1b定义为>3个转移灶。
- 基于PET的重新定义分类:Rd-M1a为单器官且≤4个病灶;Rd-M1b为>5个病灶或多器官转移。
临床怎么用
- 治疗前18F-FDG PET/CT可辅助评估新发转移性鼻咽癌的转移负荷与分布,为M1分层提供参考。
- 在临床决策中可关注转移灶数目与器官分布,但优化分类尚未经外部验证,不宜直接替代AJCC分期。
局限性
- 单中心回顾性研究,样本量有限,结论需外部验证确认。
- 优化分类为初步探索性证据,尚未在前瞻性队列中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To validate the American Joint Committee on Cancer (AJCC) 9th edition M1-stage subdivision for de novo metastatic nasopharyngeal carcinoma (DM-NPC) and explore preliminary evidence for a refined classification using 18F-FDG positron emission tomography/computed tomography (PET/CT)-derived metastatic burden. PATIENTS AND METHODS: A retrospective cohort of 185 DM-NPC patients diagnosed between 2000 and 2022, who underwent pretreatment 18F-FDG PET/CT, was analyzed. Recursive partitioning analysis (RPA) identified prognostic cutoffs for metastatic lesions. Survival outcomes were compared between AJCC 9th edition M1 subgroups (M1a: ≤3 lesions; M1b: >3 lesions) and a redefined PET-based classification (Rd-M1a: single-organ, ≤4 lesions; Rd-M1b: >5 lesions or multiorgan). RESULTS: Patients with single-organ metastases and ≤4 lesions showed potentially superior overall survival (OS) (2-y OS: 60.4% vs. 29.0%; 3-y OS: 46.2% vs. 19.6%; P<0.001). Higher metastatic burden (>5 lesions) was independently associated with worse OS (HR: 1.81; 95% CI: 1.24-2.64; P=0.002). The redefined classification suggested better prognostic discrimination than the AJCC 9th edition (C-index: 0.594 vs. 0.562; AUC at 36 mo: 0.649 vs. 0.598). Patients classified as Rd-M1b had a significantly unfavorable OS compared with those in the Rd-M1a group (HR: 2.02, 95% CI: 1.39-2.92; P=0.002). CONCLUSIONS: These preliminary findings suggest that 18F-FDG PET/CT may enhance M1-stage stratification by quantifying metastatic burden and distribution in patients with DM-NPC, potentially offering improved prognostic accuracy. However, as a single-institution retrospective study, external validation is essential to confirm these observations and guide personalized treatment strategies.
引用
- Chen SH, Cheng NM, Fan KS, et al. Refining M1-Stage Stratification in De Novo Metastatic Nasopharyngeal Carcinoma Using 18F-FDG PET/CT: Preliminary Evidence. Clin Nucl Med. 2026. PMID: 41632574. doi:10.1097/RLU.0000000000006292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。